第5版世界卫生组织分类(WHO 2022)与国际共识分类对MDS-SFB31提案的验证与比较
该研究分析了125例连续SFB31突变或环状铁粒幼红细胞≥15%且无原始细胞增多的MDS病例,验证WHO 2022与ICC对MDS-SFB31的诊断标准。结果显示SFB31阴性MDS伴RS临床特征与预后显著不同,WHO 2022中≥15% RS可替代SF3B1突变在排除高危遗传特征后两组预后相似,VAF<10%者生存较短支持ICC的10%阈值,多系病态造血者总生存显著短于单系病态造血。
要点
- WHO 2022中≥15%环状铁粒幼红细胞可替代SF3B1突变诊断MDS-SFB31,排除高危遗传特征后两组预后相似。
- SFB31突变等位基因频率<10%的患者生存期趋于更短,支持ICC设定的10%阈值。
- 多系病态造血患者总生存期显著短于单系病态造血患者,在WHO 2022和ICC定义的MDS-SF3B1中均为不良预后形态学标志。
核心结论
- WHO 2022中≥15%环状铁粒幼红细胞可替代SF3B1突变用于诊断MDS-SFB31,排除高危遗传特征后两组预后相似。
- SFB31突变等位基因频率<10%的患者生存期趋于更短,支持ICC的10%阈值。
- 多系病态造血在WHO 2022和ICC定义的MDS-SF3B1中仍是预后不良的强力形态学标志。
研究设计与样本
- 研究分析了125例连续MDS病例,纳入标准为SFB31突变或环状铁粒幼红细胞≥15%且无原始细胞增多。
主要发现
- SFB31阴性MDS伴环状铁粒幼红细胞的患者临床特征显著不同且预后更差。
- 按WHO 2022,检测到≥15%环状铁粒幼红细胞可替代SF3B1突变,排除WHO 2022所指高危遗传特征后两组预后相似,支持该提案。
- SFB31突变等位基因频率<10%的患者生存期趋于更短,支持ICC的10%阈值。
- 多系病态造血患者的总生存期显著短于单系病态造血患者。
关键数值与推荐
- WHO 2022提出≥15%环状铁粒幼红细胞可替代SF3B1突变诊断MDS-SFB31。
- ICC设定SFB31突变等位基因频率10%为阈值。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The criteria of myelodysplastic syndromes (MDS) with mutated SFB31 (MDS-SFB31) proposed by the 5th edition of the WHO classification (WHO 2022) and the International Consensus Classification (ICC) need validation. We analysed 125 consecutive MDS cases with SFB31 mutation or ring sideroblasts (RS) ≥15% without excess blasts. We found that SFB31-negative MDS with RS had significantly different clinical features and worse prognosis. According to WHO 2022, the detection of ≥15% RS may substitute for SF3B1 mutation and our analyses support this proposal for similar prognosis of two groups after excluding high-risk genetic features referred by WHO 2022. Patients with variant allele frequency (VAF) <10% SFB31 tend to have briefer survival, supporting the VAF 10% threshold of ICC. Patients with multilineage dysplasia (MLD) had significantly shorter OS than those with single lineage dysplasia. MLD is still a powerful morphological marker of worse outcome in WHO 2022 and ICC-defined MDS-SF3B1.
引用
- Liu L, Li B, Xu Z, et al. Validation and comparison of 5th edition World Health Organization classification (WHO 2022) and International Consensus Classification proposals for MDS-SFB31. Br J Haematol. 2024. PMID: 38654443. doi:10.1111/bjh.19482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。